<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390156</url>
  </required_header>
  <id_info>
    <org_study_id>06991</org_study_id>
    <secondary_id>06991</secondary_id>
    <secondary_id>H9672-28868</secondary_id>
    <secondary_id>CSTI571BUS245</secondary_id>
    <nct_id>NCT00390156</nct_id>
  </id_info>
  <brief_title>Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I Trial of Imatinib, Bevacizumab, &amp; Metronomic Cyclophosphamide as Antiangiogenic Therapy in Refractory Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in&#xD;
      different ways. Some block the ability of tumor cells to grow and spread. Others find tumor&#xD;
      cells and help kill them or carry tumor-killing substances to them. Drugs used in&#xD;
      chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Bevacizumab and&#xD;
      cyclophosphamide may also stop the growth of tumor cells by blocking blood flow to the tumor.&#xD;
      Imatinib and bevacizumab may help cyclophosphamide work better by making tumor cells more&#xD;
      sensitive to the drug. Giving cyclophosphamide once a day together with imatinib and&#xD;
      bevacizumab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of imatinib when given&#xD;
      together with bevacizumab and cyclophosphamide in treating patients with refractory&#xD;
      metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of imatinib when given together with bevacizumab&#xD;
           and metronomic cyclophosphamide in patients with refractory metastatic solid tumors.&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effects of cyclophosphamide and bevacizumab on imatinib pharmacokinetics.&#xD;
&#xD;
        -  Determine if patients treated with this regimen achieve plasma levels of&#xD;
           cyclophosphamide that are predicted to be antiangiogenic.&#xD;
&#xD;
        -  Determine the effects of this regimen on the number of circulating endothelial cells,&#xD;
           endothelial progenitor cells, activated endothelial cells, and circulating tumor cells.&#xD;
&#xD;
        -  Determine the effects of this regimen on parameters measured by CT scan perfusion (e.g.,&#xD;
           regional blood flow, blood volume, permeability-surface area product, and mean transit&#xD;
           time).&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, pilot, dose-escalation study of imatinib.&#xD;
&#xD;
      Patients receive oral cyclophosphamide and oral imatinib once daily on days 1-28 and&#xD;
      bevacizumab IV on days 1 and 15. Treatment repeats every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of imatinib until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of imatinib when given together with bevacizumab and metronomic cyclophosphamide</measure>
    <time_frame>Safety data will be assessed after 3 patients and 6 patients complete 42 days of study treatment to determine whether to dose escalate to the next cohort.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of imatinib</measure>
    <time_frame>After the last patient completes PKs on Cycle 1 Day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of imatinib in combination with cyclophosphamide and bevacizumab</measure>
    <time_frame>After all patients have completed study therapy. Safety data will be monitored throughout the study.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>Unspecified Adult Solid Tumor</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>5 mg/kg</description>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Current dose 50 mg</description>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib</intervention_name>
    <description>Current dose 400 mg</description>
    <other_name>Gleevec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of solid tumor&#xD;
&#xD;
               -  Advanced or metastatic disease* NOTE: *With the exception of colorectal and lung&#xD;
                  cancer patients, all patients must receive approval from the insurance carrier&#xD;
                  that allows for coverage/payment of the study drug bevacizumab&#xD;
&#xD;
          -  Refractory to standard therapy OR no standard therapy exists&#xD;
&#xD;
          -  No advanced ovarian cancer or peritoneal carcinomatosis&#xD;
&#xD;
          -  No metastases from any cancer causing significant ascites&#xD;
&#xD;
          -  No lung malignancy with any of the following characteristics:&#xD;
&#xD;
               -  In close proximity to a major vessel&#xD;
&#xD;
               -  Centrally located&#xD;
&#xD;
               -  Cavitary&#xD;
&#xD;
               -  Squamous histology&#xD;
&#xD;
               -  Hemoptysis &gt; ½ teaspoon per day&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Bilirubin &lt; 2 mg/dL&#xD;
&#xD;
          -  AST or ALT &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  Creatinine &lt; 2 mg/dL&#xD;
&#xD;
          -  Urine protein:creatinine ratio ≤ 1.0&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to tolerate oral therapy&#xD;
&#xD;
          -  No bleeding diatheses or coagulopathy&#xD;
&#xD;
          -  No impairment of gastrointestinal (GI) function or GI disease that may affect or alter&#xD;
             absorption of imatinib mesylate and/or cyclophosphamide (e.g., malabsorption syndrome,&#xD;
             history of total gastrectomy/significant small bowel resection)&#xD;
&#xD;
          -  No abdominal fistula, GI perforation, or intra-abdominal abscess within the past 6&#xD;
             months&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., blood pressure &gt; 150/100 mm Hg)&#xD;
&#xD;
          -  No uncontrolled cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Coronary artery disease&#xD;
&#xD;
               -  Uncontrolled cardiac arrhythmia&#xD;
&#xD;
               -  Symptomatic congestive heart failure (i.e., New York Heart Association class&#xD;
                  II-IV)&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Clinically significant peripheral vascular disease&#xD;
&#xD;
          -  No arterial thromboses within the past year, including any of the following:&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Cerebrovascular event&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Angina requiring medical or surgical intervention&#xD;
&#xD;
               -  Clinically significant peripheral artery disease&#xD;
&#xD;
               -  Any other arterial thromboembolic event&#xD;
&#xD;
          -  No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the&#xD;
             lung&#xD;
&#xD;
          -  No serious nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No other active second malignancy except nonmelanoma skin cancer or cervical carcinoma&#xD;
             in situ unless therapy has been completed and &lt; 30% risk for relapse exists&#xD;
&#xD;
          -  No active infection or known HIV infection&#xD;
&#xD;
          -  No history of allergic reactions (≥ grade 3 or 4) to compounds of similar chemical or&#xD;
             biologic composition to cyclophosphamide (i.e., alkylating agents)&#xD;
&#xD;
          -  No history of noncompliance with medical regimens&#xD;
&#xD;
          -  No known intolerance or hypersensitivity reaction to bevacizumab, imatinib mesylate,&#xD;
             or cyclophosphamide&#xD;
&#xD;
          -  No other significant medical illness, psychiatric illness, or social situation that,&#xD;
             in the opinion of the investigator, would limit compliance with study requirements&#xD;
&#xD;
          -  No inability to grant reliable informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No major surgical procedure within the past 28 days or anticipated major surgery&#xD;
             during study treatment except for placement of a venous access device or surgery for a&#xD;
             diagnostic study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily K. Bergsland, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-1705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory</keyword>
  <keyword>prior treatment</keyword>
  <keyword>solid tumors</keyword>
  <keyword>phase I</keyword>
  <keyword>phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

